{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:22:10Z","timestamp":1790371330346,"version":"4.1.0"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jneuroim.2023.578062","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T01:59:00Z","timestamp":1678067940000},"page":"578062","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["The therapeutic effect of ofatumumab in autoimmune encephalitis: A case series"],"prefix":"10.1016","volume":"377","author":[{"given":"Qinming","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dou","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2023.578062_bb0005","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1177\/13524585211044479","article-title":"Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study","volume":"28","author":"Bar-Or","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2023.578062_bb0010","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/ane.12963","article-title":"Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - outlier or predecessor?","volume":"138","author":"Berntsson","year":"2018","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jneuroim.2023.578062_bb0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1590\/0004-282x20170176","article-title":"Autoimmune encephalitis: a review of diagnosis and treatment","volume":"76","author":"Dutra","year":"2018","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.jneuroim.2023.578062_bb0020","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in Multiple Sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2023.578062_bb0025","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"ANN. NEUROL."},{"key":"10.1016\/j.jneuroim.2023.578062_bb0030","article-title":"Rituximab in treatment for neuroimmunological diseases","volume":"80","author":"Schr\u00f6der","year":"2009","journal-title":"Nervenarzt"},{"key":"10.1016\/j.jneuroim.2023.578062_bb0035","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001088","article-title":"Rituximab treatment and long-term outcome of patients with autoimmune encephalitis: real-world evidence from the GENERATE registry","volume":"8","author":"Thaler","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.jneuroim.2023.578062_bb0040","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/practneurol-2020-002567","article-title":"Autoimmune encephalitis: clinical spectrum and management","volume":"21","author":"Uy","year":"2021","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.jneuroim.2023.578062_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2019.577114","article-title":"Anti-dipeptidyl-peptidase-like protein 6 encephalitis, a rare cause of reversible rapid progressive dementia and insomnia","volume":"339","author":"Zhou","year":"2020","journal-title":"J. Neuroimmunol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572823000486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572823000486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:42:18Z","timestamp":1759048938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572823000486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":9,"alternative-id":["S0165572823000486"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578062","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The therapeutic effect of ofatumumab in autoimmune encephalitis: A case series","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"578062"}}